Sinovac Biotech (Sinovac Biotech) Cash Conversion Cycle : 368.90 (As of Jun. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Sinovac Biotech's Days Sales Outstanding for the six months ended in Jun. 2023 was 599.39.
Sinovac Biotech's Days Inventory for the six months ended in Jun. 2023 was 176.03.
Sinovac Biotech's Days Payable for the six months ended in Jun. 2023 was 406.52.
Therefore, Sinovac Biotech's Cash Conversion Cycle (CCC) for the six months ended in Jun. 2023 was 368.90.

Sinovac Biotech Cash Conversion Cycle Historical Data

The historical data trend for Sinovac Biotech's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Cash Conversion Cycle Chart

Sinovac Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash Conversion Cycle

Get a 7-Day Free Trial

348.54

371.22

394.06

77.81

301.10

Sinovac Biotech Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash Conversion Cycle	Get a 7-Day Free Trial															-55.09	-23.35	232.02	496.97	368.90

Competitive Comparison of Sinovac Biotech's Cash Conversion Cycle

For the Biotechnology subindustry, Sinovac Biotech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinovac Biotech's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's Cash Conversion Cycle falls into.

Sinovac Biotech Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Sinovac Biotech's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	173.7	+	148.31	-	20.91
	=	301.10

Sinovac Biotech's Cash Conversion Cycle for the quarter that ended in Jun. 2023 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	599.39	+	176.03	-	406.52
	=	368.90

Sinovac Biotech (NAS:SVA) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Sinovac Biotech Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinovac Biotech (Sinovac Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Executives

Lily Wang	director, 10 percent owner, officer: Chief Financial Officer	300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc	10 percent owner	PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong	director, 10 percent owner, officer: President and CEO
Terry G Bowering	director, 10 percent owner, officer: President, CEO	10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6